ZOPICLONE
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N05C, N05CF) — coverage varies; not interchangeable
- Zolpidem (Sublinox): not a benefit
- Flurazepam (Dalmane): general benefit, Not a benefit
- Nitrazepam (Mogadon): general benefit
- Temazepam (Restoril): general benefit
- Triazolam (Halcion): general benefit, Not a benefit
- Midazolam (Versed): limited Use 495, 496, Not a benefit
Jamp Zopiclone · DIN 02549271 · 3.75mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imovane + generic brands; DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Zopiclone · DIN 02549271
Manufacturer: Jamp Pharma Corporation; listing date 2025-05-30
Health Canada: Marketed since 2025-03-26 · brand JAMP ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 3.75 MG · company Jamp pharma corporation · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103814 · Verify on the e-Formulary ↗ (DIN 02549271)
Source record
DIN 02549271: Jamp Zopiclone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400243; group id 531; item number 1435; lccId None; manufacturer id JPC
Source form: Tab; strength: 3.75mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2343; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549271
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103814
Interchangeable products
Imovane · DIN 02125285 · not recorded
PMS-Zopiclone · DIN 02458543 · not recorded
Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-10-27, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549271
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Zopiclone · DIN 02458543 · 3.75mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access criteria on record are for Brand(s): Imovane + generic brands; DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Zopiclone · DIN 02458543
Manufacturer: Pharmascience Inc.; listing date 2025-07-31
Health Canada: Marketed since 2017-01-01 · brand PMS-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 3.75 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94567 · Verify on the e-Formulary ↗ (DIN 02458543)
Source record
DIN 02458543: PMS-Zopiclone
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400243; group id 531; item number 1435; lccId None; manufacturer id PMS
Source form: Tab; strength: 3.75mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2343; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458543
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94567
Interchangeable products
Imovane · DIN 02125285 · not recorded
Jamp Zopiclone · DIN 02549271 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02458543
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Zopiclone · DIN 02475839 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
AG-Zopiclone · DIN 02475839
Manufacturer: Angita Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2018-07-25 · brand AG-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Angita pharma inc. · schedule Prescription
AG-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96656 · Verify on the e-Formulary ↗ (DIN 02475839)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02475839).
DIN 02475839: AG-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id ANG
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475839
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96656
Interchangeable products
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475839
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Zopiclone · DIN 02245077 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Apo-Zopiclone · DIN 02245077
Manufacturer: Apotex Inc.; listing date 2007-09-04
Health Canada: Marketed since 2002-06-04 · brand APO-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Apotex inc · schedule Prescription
Apo-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69081 · Verify on the e-Formulary ↗ (DIN 02245077)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02245077).
DIN 02245077: Apo-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245077
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69081
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: resolved shortage (ended 2024-02-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245077
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Zopiclone · DIN 02549298 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Jamp Zopiclone · DIN 02549298
Manufacturer: Jamp Pharma Corporation; listing date 2025-09-29
Health Canada: Marketed since 2025-08-08 · brand JAMP ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103816 · Verify on the e-Formulary ↗ (DIN 02549298)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02549298).
DIN 02549298: Jamp Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549298
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103816
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549298
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Zopiclone Tablets · DIN 02406969 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Jamp-Zopiclone Tablets · DIN 02406969
Manufacturer: Jamp Pharma Corporation; listing date 2013-08-29
Health Canada: Marketed since 2014-01-08 · brand JAMP-ZOPICLONE TABLETS · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Zopiclone Tablets: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89162 · Verify on the e-Formulary ↗ (DIN 02406969)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02406969).
DIN 02406969: Jamp-Zopiclone Tablets
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406969
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89162
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406969
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Zopiclone · DIN 02467941 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
M-Zopiclone · DIN 02467941
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2018-04-16 · brand M-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Mantra pharma inc · schedule Prescription
M-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95631 · Verify on the e-Formulary ↗ (DIN 02467941)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02467941).
DIN 02467941: M-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id MAT
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467941
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95631
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: resolved shortage (ended 2021-03-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467941
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Zopiclone · DIN 02386771 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Mar-Zopiclone · DIN 02386771
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-08-27
Health Canada: Marketed since 2013-04-17 · brand MAR-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87237 · Verify on the e-Formulary ↗ (DIN 02386771)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02386771).
DIN 02386771: Mar-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id MAR
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386771
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87237
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386771
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Zopiclone · DIN 02391716 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Mint-Zopiclone · DIN 02391716
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-12-21
Health Canada: Marketed since 2012-10-10 · brand MINT-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87703 · Verify on the e-Formulary ↗ (DIN 02391716)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02391716).
DIN 02391716: Mint-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02391716
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87703
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: resolved shortage (ended 2020-11-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02391716
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Zopiclone · DIN 02477378 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
NRA-Zopiclone · DIN 02477378
Manufacturer: Nora Pharma; listing date 2020-08-28
Health Canada: Marketed since 2018-08-30 · brand NRA-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Nora pharma inc · schedule Prescription
NRA-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96835 · Verify on the e-Formulary ↗ (DIN 02477378)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02477378).
DIN 02477378: NRA-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477378
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96835
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477378
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Zopiclone · DIN 02243426 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
PMS-Zopiclone · DIN 02243426
Manufacturer: Pharmascience Inc.; listing date 2007-09-04
Health Canada: Marketed since 2001-02-15 · brand PMS-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Pharmascience inc · schedule Prescription
PMS-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67334 · Verify on the e-Formulary ↗ (DIN 02243426)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243426).
DIN 02243426: PMS-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243426
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67334
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: resolved shortage (ended 2017-12-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243426
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ratio-Zopiclone · DIN 02246534 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Ratio-Zopiclone · DIN 02246534
Manufacturer: Ratiopharm Inc.; listing date 2007-09-04
Health Canada: Marketed since 2020-08-13 · brand TEVA-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Teva canada limited · schedule Prescription
Ratio-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70717 · Verify on the e-Formulary ↗ (DIN 02246534)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02246534).
DIN 02246534: Ratio-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id RPH
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246534
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70717
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: resolved shortage (ended 2024-06-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246534
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Zopiclone · DIN 02278030 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Riva-Zopiclone · DIN 02278030
Manufacturer: Laboratoire Riva Inc.; listing date 2022-05-31
Health Canada: Marketed since 2006-10-10 · brand RIVA-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76362 · Verify on the e-Formulary ↗ (DIN 02278030)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02278030).
DIN 02278030: Riva-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id RIA
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02278030
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76362
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02278030
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Zopiclone · DIN 02344122 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Zopiclone · DIN 02344122
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2013-10-18 · brand ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Sanis health inc · schedule Prescription
Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82952 · Verify on the e-Formulary ↗ (DIN 02344122)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02344122).
DIN 02344122: Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02344122
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82952
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02385821 · $0.2231
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02344122
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Zopiclone · DIN 02385821 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Zopiclone · DIN 02385821
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28
Health Canada: Marketed since 2018-07-26 · brand ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Zopiclone: Formulary list price $0.2231/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2231 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87144 · Verify on the e-Formulary ↗ (DIN 02385821)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02385821).
DIN 02385821: Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400064; group id 531; item number 1436; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2231; ministry $0.2231
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385821
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87144
Interchangeable products
AG-Zopiclone · DIN 02475839 · $0.2231
Apo-Zopiclone · DIN 02245077 · $0.2231
Co Zopiclone · DIN 02271931 · $0.2231
Imovane · DIN 02216167 · not recorded
Jamp Zopiclone · DIN 02549298 · $0.2231
Jamp-Zopiclone Tablets · DIN 02406969 · $0.2231
M-Zopiclone · DIN 02467941 · $0.2231
Mar-Zopiclone · DIN 02386771 · $0.2231
Mint-Zopiclone · DIN 02391716 · $0.2231
NRA-Zopiclone · DIN 02477378 · $0.2231
PMS-Zopiclone · DIN 02243426 · $0.2231
Ran-Zopiclone · DIN 02267918 · $0.2231
Ratio-Zopiclone · DIN 02246534 · $0.2231
Riva-Zopiclone · DIN 02278030 · $0.2231
Sandoz Zopiclone · DIN 02257572 · $0.2231
Septa-Zopiclone · DIN 02386909 · $0.2231
Zopiclone · DIN 02344122 · $0.2231
Shortage status: resolved shortage (ended 2018-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385821
Shortage record checked 2026-09-13T08:10:21.292534+00:00
AG-Zopiclone · DIN 02475847 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
AG-Zopiclone · DIN 02475847
Manufacturer: Angita Pharma Inc.; listing date 2021-09-30
Health Canada: Marketed since 2018-07-25 · brand AG-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Angita pharma inc. · schedule Prescription
AG-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96657 · Verify on the e-Formulary ↗ (DIN 02475847)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02475847).
DIN 02475847: AG-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id ANG
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475847
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96657
Interchangeable products
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02475847
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Zopiclone · DIN 02218313 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Apo-Zopiclone · DIN 02218313
Manufacturer: Apotex Inc.; listing date 2007-09-04
Health Canada: Marketed since 1996-09-19 · brand APO-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Apotex inc · schedule Prescription
Apo-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43233 · Verify on the e-Formulary ↗ (DIN 02218313)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02218313).
DIN 02218313: Apo-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id APX
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02218313
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43233
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: resolved shortage (ended 2026-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02218313
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Imovane · DIN 01926799 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)Savings card: RxHelp ONE lists IMOVANE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Imovane · DIN 01926799
Manufacturer: Sanofi Aventis Pharma; listing date 2007-09-04
Health Canada: Marketed since 2006-06-13 · brand IMOVANE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Sanofi-aventis canada inc · schedule Prescription
Imovane: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12426 · Verify on the e-Formulary ↗ (DIN 01926799)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 01926799).
DIN 01926799: Imovane
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id SAV
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926799
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12426
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: resolved shortage (ended 2019-02-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01926799
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Zopiclone · DIN 02549301 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Jamp Zopiclone · DIN 02549301
Manufacturer: Jamp Pharma Corporation; listing date 2025-06-30
Health Canada: Marketed since 2025-08-28 · brand JAMP ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103817 · Verify on the e-Formulary ↗ (DIN 02549301)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02549301).
DIN 02549301: Jamp Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id JPC
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549301
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103817
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549301
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Zopiclone Tablets · DIN 02406977 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Jamp-Zopiclone Tablets · DIN 02406977
Manufacturer: Jamp Pharma Corporation; listing date 2015-03-31
Health Canada: Marketed since 2014-11-19 · brand JAMP-ZOPICLONE TABLETS · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Zopiclone Tablets: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89163 · Verify on the e-Formulary ↗ (DIN 02406977)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02406977).
DIN 02406977: Jamp-Zopiclone Tablets
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id JPC
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406977
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89163
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406977
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Zopiclone · DIN 02467968 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
M-Zopiclone · DIN 02467968
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2018-04-16 · brand M-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Mantra pharma inc · schedule Prescription
M-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95632 · Verify on the e-Formulary ↗ (DIN 02467968)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02467968).
DIN 02467968: M-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id MAT
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467968
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95632
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467968
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Zopiclone · DIN 02386798 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Mar-Zopiclone · DIN 02386798
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-08-27
Health Canada: Marketed since 2013-04-17 · brand MAR-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87238 · Verify on the e-Formulary ↗ (DIN 02386798)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02386798).
DIN 02386798: Mar-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id MAR
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386798
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87238
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386798
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Zopiclone · DIN 02391724 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
Mint-Zopiclone · DIN 02391724
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-12-21
Health Canada: Marketed since 2012-10-10 · brand MINT-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87704 · Verify on the e-Formulary ↗ (DIN 02391724)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02391724).
DIN 02391724: Mint-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id MIN
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02391724
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87704
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
NRA-Zopiclone · DIN 02477386 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02391724
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Zopiclone · DIN 02477386 · 7.5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗) Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Zopiclone
Brand(s): Imovane + generic brands
DOSAGE FORM/ STRENGTH: 5 mg, 7.5 mg tablet
For the treatment of insomnia as a single hypnotic agent in patients who meet the
following criteria;
• Have failed at least two benzodiazepines; OR
• Have failed or experienced intolerance to at least one benzodiazepine and one
other hypnotic (i.e., amitriptyline, trazodone, etc)
Duration of Approval: 2 Years
For the treatment of insomnia if patient has an identified psychiatric diagnosis.
Renewals will be considered in patients who are responding to therapy AND who
continues to require therapy AND who are using zopiclone as a single agent.
Duration of Approval: 2 Years
160
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 160, record 93, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)1 brand, same coverage
NRA-Zopiclone · DIN 02477386
Manufacturer: Nora Pharma; listing date 2020-08-28
Health Canada: Marketed since 2018-08-30 · brand NRA-ZOPICLONE · ATC N05CF01 ZOPICLONE · form Tablet · route Oral · ingredients ZOPICLONE 7.5 MG · company Nora pharma inc · schedule Prescription
NRA-Zopiclone: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96836 · Verify on the e-Formulary ↗ (DIN 02477386)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02477386).
DIN 02477386: NRA-Zopiclone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 282400179; group id 531; item number 1437; lccId None; manufacturer id NRA
Source form: Tab; strength: 7.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02477386
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96836
Interchangeable products
AG-Zopiclone · DIN 02475847 · $0.4685
Apo-Zopiclone · DIN 02218313 · $0.4685
Co Zopiclone · DIN 02271958 · $0.4685
Imovane · DIN 01926799 · not recorded
Jamp Zopiclone · DIN 02549301 · $0.4685
Jamp-Zopiclone · DIN 02356805 · $0.4685
Jamp-Zopiclone Tablets · DIN 02406977 · $0.4685
M-Zopiclone · DIN 02467968 · $0.4685
Mar-Zopiclone · DIN 02386798 · $0.4685
Mint-Zopiclone · DIN 02391724 · $0.4685
PMS-Zopiclone · DIN 02240606 · $0.4685
Ran-Zopiclone · DIN 02267926 · $0.4685
Ratio-Zopiclone · DIN 02242481 · $0.4685
Riva-Zopiclone · DIN 02278049 · $0.4685
Sandoz Zopiclone Tablet · DIN 02008203 · $0.4685
Septa-Zopiclone · DIN 02386917 · $0.4685
Zopiclone · DIN 02282445 · $0.4685
Zopiclone · DIN 02385848 · $0.4685
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02477386
Shortage record checked 2026-09-13T08:10:21.292534+00:00